{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:46:08Z","timestamp":1786992368951,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000006","name":"Association of Medical Microbiology and Infectious Disease Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015631","name":"Merck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jgar.2023.03.010","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T12:27:50Z","timestamp":1680784070000},"page":"171-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry"],"prefix":"10.1016","volume":"33","author":[{"given":"George","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Mirzanejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0962-4437","authenticated-orcid":false,"given":"Anna","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Dhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Werry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-9534","authenticated-orcid":false,"given":"Jean-Francois","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Girourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8976-8902","authenticated-orcid":false,"given":"Teagen Rolf","family":"von den Baumen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2023.03.010_bib0001","article-title":"Oral and intravenous fosfomycin for the treatment of complicated urinary tract infections","volume":"28","author":"Zhanel","year":"2020","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.jgar.2023.03.010_bib0002","article-title":"Intravenous fosfomycin: an assessment of its potential for use in the treatment of systemic infections in Canada","volume":"25","author":"Zhanel","year":"2018","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.jgar.2023.03.010_bib0003","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/phar.2326","article-title":"Parenteral fosfomycin for the treatment of multidrug resistant bacterial infections: the rise of the epoxide","volume":"39","author":"Trinh","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2023.03.010_bib0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkz283","article-title":"42936 pathogens from Canadian hospitals: 10 years of results (2007\u201316) from the CANWARD surveillance study","volume":"74","author":"Zhanel","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.03.010_bib0005","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/jac\/dkac275","article-title":"In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study","volume":"77","author":"Karlowsky","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.03.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38691","article-title":"The role of intravenous fosfomycin: finding our way out of Dante's forest dark","volume":"5","author":"Tamma","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jgar.2023.03.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jgar.2023.03.010_bib0008","first-page":"1055","article-title":"A real-world study on prescription pattern of fosfomycin in critical care patients","volume":"25","author":"Zirpe","year":"2021","journal-title":"Ind J Crit Care Med"},{"key":"10.1016\/j.jgar.2023.03.010_bib0009","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3855\/jidc.14125","article-title":"Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon","volume":"15","author":"Ballouz","year":"2021","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.jgar.2023.03.010_bib0010","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.jiph.2021.09.025","article-title":"Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections","volume":"14","author":"Abdallah","year":"2021","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jgar.2023.03.010_bib0011","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/ajhp\/zxab294","article-title":"Intravenous fosfomycin as salvage therapy for osteomyelitis caused by multidrug-resistant Pseudomonas aeruginosa","volume":"78","author":"Wong","year":"2021","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jgar.2023.03.010_bib0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14787210.2021.1932463","article-title":"Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review","volume":"20","author":"Tsegka","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2023.03.010_bib0013","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s10096-021-04181-x","article-title":"Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies","volume":"40","author":"Antonello","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2023.03.010_bib0014","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/antibiotics9080500","article-title":"Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies","volume":"9","author":"Antonello","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2023.03.010_bib0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/14787210.2020.1754193","article-title":"Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence","volume":"8","author":"Tsegka","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2023.03.010_bib0016","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s15010-019-01323-4","article-title":"Current clinical use of intravenous fosfomycin in ICU patients in two European countries","volume":"47","author":"Putensen","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2023.03.010_bib0017","unstructured":"Bodmann KF, Venditti M, Bal A, Vossen M, Dimopoulos G, Litty FA. Intravenous (IV) fosfomycin for the treatment of severely infected patients (FORTRESS): an update from a European non-interventional and prospective clinical study: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) July 9-12, 2021, online, poster number 00475."},{"key":"10.1016\/j.jgar.2023.03.010_bib0018","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgar.2021.03.025","article-title":"Real-life experience with ceftolozane\/tazobactam in Canada: results from the CLEAR (Canadian leadership on antimicrobial real-life usage) registry","volume":"25","author":"Zhanel","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2023.03.010_bib0019","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jgar.2021.01.014","article-title":"Real-life experience with ceftobiprole in Canada: results from the CLEAR (Canadian leadership on antimicrobial real-life usage) registry","volume":"24","author":"Zhanel","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2023.03.010_bib0020","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/14656566.2021.1904891","article-title":"Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases","volume":"22","author":"Lynch","year":"2021","journal-title":"Exp Opin on Pharmacother"},{"issue":"1","key":"10.1016\/j.jgar.2023.03.010_bib0021","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0041-1741019","article-title":"Infections due to Acinetobacter baumannii-calcoaceticus complex: Escalation of antimicrobial resistance and evolving treatment options","volume":"43","author":"Lynch","year":"2022","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2023.03.010_bib0022","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0041-1740109","article-title":"Pseudomonas aeruginosa pneumonia: evkolution of antimicrobial resistance and implications for therapy","volume":"43","author":"Lynch","year":"2022","journal-title":"Sem Resp Crit Care Med"},{"key":"10.1016\/j.jgar.2023.03.010_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.844122","article-title":"Hypernatremia during intravenous treatment with fosfomycin: a retrospective medical record review study and an analysis of spontaneous reports in the EudraVigilance database","volume":"13","author":"Scavone","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:41Z","timestamp":1761991181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523000553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":23,"alternative-id":["S2213716523000553"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.03.010","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life experience with IV fosfomycin in Canada: Results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}